FDA puts partial clinical hold on Gilead's magrolimab + azacitidine studies
Over the current book year the total revenue from the company in Foster City will be 24.53 billion USD (consensus estimates). This is quite lower than 2021's revenue of 27.31 billion USD.
Historical revenues and results Gilead Sciences plus estimates 2021
The analysts expect for 2021 a net profit of 8.22 billion USD. For this year the majority of the analysts, consulted by press agency Thomson Reuters, expects a profit per share of 6.53 USD. The PE-ratio therefore is 8.87.
Huge dividend Gilead Sciences
Analysts expect a dividend of 2.92 USD per share. Gilead Sciences 's dividend yield thus equals 5.04 percent. The average dividend yield of the biotech companies equals a relatively high 2.64 percent.Gilead Sciences 's market capitalization is based on the number of outstanding shares around 72.63 billion USD. -4
On Thursday, the stock closed at 57.92 USD.Historical stock prices Gilead Sciences
ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.
| About us | Network | Partners |
| Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos |
Analist.nlLinksISIN
|
MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-x
|
